Female patients, if of childbearing potential, must have a negative serum pregnancy test within 72 hours prior to the date of the first dose of study medication.Xx_NEWLINE_xXFemale subjects of childbearing potential should have a negative urine or serum pregnancy within 72 hours prior to receiving the first dose of study medication; if the urine test is positive or cannot be confirmed as negative, a serum pregnancy test will be requiredXx_NEWLINE_xXFemale patients must have a negative pregnancy test (blood or urine) within 14 days prior to registrationXx_NEWLINE_xXWOCBP must have a negative pregnancy test (serum or urine).Xx_NEWLINE_xXFemale patients of childbearing potential must have a negative serum or urine pregnancy testXx_NEWLINE_xXFemale patients of childbearing potential must have a negative urine or serum pregnancy test within 72 hours prior to receiving the first dose of study medication. If the urine test is positive or cannot be confirmed as negative, a serum pregnancy test will be required.Xx_NEWLINE_xXFemale child-bearing potential must have a negative urine or serum pregnancy test within 72 hours prior to receiving the first dose of study medicationXx_NEWLINE_xXFemale subject of childbearing potential should have a negative urine or serum pregnancy within 72 hours prior to receiving the first dose of study medication; if the urine test is positive or cannot be confirmed as negative, a serum pregnancy test will be requiredXx_NEWLINE_xXNegative serum pregnancy test at screeningXx_NEWLINE_xXNegative serum or urine pregnancy test within 7 days prior to starting treatmentXx_NEWLINE_xXNegative urine pregnancy test done =< 7 days prior to registration, for women of childbearing potential only\r\n* NOTE: If the urine test is positive or cannot be confirmed as negative, a serum pregnancy test will be requiredXx_NEWLINE_xXFemale subject of childbearing potential should have a negative urine or serum pregnancy within 14 days prior to receiving the first dose of study medication; if the urine test is positive or cannot be confirmed as negative, a serum pregnancy test will be requiredXx_NEWLINE_xXA negative pregnancy test (if female)Xx_NEWLINE_xXFemale subject of childbearing potential should have a negative urine or serum pregnancy within 72 hours prior to receiving the first dose of study medication; if the urine test is positive or cannot be confirmed as negative, a serum pregnancy test will be requiredXx_NEWLINE_xXFemale subjects of childbearing potential should have a negative urine or serum pregnancy within 72 hours prior to receiving the first dose of study medication; if the urine test is positive or cannot be confirmed as negative, a serum pregnancy test will be requiredXx_NEWLINE_xXFemale subject of child-bearing potential, as defined above, must have a negative urine or serum pregnancy within 7 days prior to receiving the first dose of study medication; if a urine test is positive or cannot be confirmed as negative, a serum pregnancy test will be requiredXx_NEWLINE_xXFemale subject of childbearing potential should have a negative urine or serum pregnancy within 72 hours prior to receiving the first dose of study medication; if the urine test is positive or cannot be confirmed as negative, a serum pregnancy test will be requiredXx_NEWLINE_xXFemale patient of childbearing potential has a negative serum or urine pregnancy within 72 hours prior to receiving the first dose of study medicationXx_NEWLINE_xXCOHORT 1: Female subject of childbearing potential should have a negative urine or serum pregnancy within 72 hours prior to receiving the first dose of study medication; if the urine test is positive or cannot be confirmed as negative, a serum pregnancy test will be requiredXx_NEWLINE_xXCOHORT 2: Female subject of childbearing potential should have a negative urine or serum pregnancy within 72 hours prior to receiving the first dose of study medication; if the urine test is positive or cannot be confirmed as negative, a serum pregnancy test will be requiredXx_NEWLINE_xXFemales at reproductive age must have a negative urine pregnancy test prior to entry to this studyXx_NEWLINE_xXFemale patients must have a negative urine pregnancy test within 7 days prior to registration; if urine test is positive, it should be followed by serum pregnancy testXx_NEWLINE_xXSAFETY RUN-IN: Female subject of childbearing potential should have a negative urine or serum pregnancy within 72 hours prior to registration; if the urine test is positive or cannot be confirmed as negative, a serum pregnancy test will be requiredXx_NEWLINE_xXRANDOMIZED PHASE II CLINICAL TRIAL: Female subject of childbearing potential should have a negative urine or serum pregnancy within 72 hours prior to registration; if the urine test is positive or cannot be confirmed as negative, a serum pregnancy test will be requiredXx_NEWLINE_xXNegative serum pregnancy testXx_NEWLINE_xXFemale subject of childbearing potential should have a negative urine or serum pregnancy test within 72 hours prior to receiving the first dose of study medication; if the urine test is positive or cannot be confirmed as negative, a serum pregnancy test will be requiredXx_NEWLINE_xXIf the participant is a female of childbearing potential, must have had a negative serum or urine pregnancy test within 14 days of the first dose of study drug and must not be breast feedingXx_NEWLINE_xXNegative serum pregnancy test within 7 days prior to starting treatmentXx_NEWLINE_xXPregnant and/or breastfeeding; patient must have a negative pregnancy test within 72 hours of start of study treatmentXx_NEWLINE_xXFemale participants of childbearing potential should have a negative urine or serum pregnancy test within 72 hours prior to receiving the first dose of study drugXx_NEWLINE_xXFCBP must have a negative serum or urine pregnancy test and agree to birth control.Xx_NEWLINE_xXFemale patients must have a negative pregnancy testXx_NEWLINE_xXFemale subjects must either be of non-reproductive potential, not breast-feeding or must have a negative urine or serum pregnancy test within 28 days of study treatment, confirmed prior to treatment on day 1.Xx_NEWLINE_xXA negative serum pregnancy testXx_NEWLINE_xXFemale subjects of childbearing potential must have a negative serum or urine pregnancy test within 8 days of initiating protocol therapyXx_NEWLINE_xXFemale subjects of childbearing potential must have a negative serum or urine pregnancy test within 8 days of initiating protocol therapyXx_NEWLINE_xXFemale subjects of child-bearing potential must have a negative urine pregnancy test within 72 hours prior to receiving the first dose of study medication. If a urine test is positive or cannot be confirmed as negative, a serum pregnancy test will be required.Xx_NEWLINE_xXIf female, the subject must have a negative serum or urine pregnancy test at Screening unless meeting non-productive potential criteria.Xx_NEWLINE_xXEither of non-reproductive potential (i.e., post-menopausal by history of age >= 50 years old and no menses for >= 1 year without an alternative medical cause; OR history of hysterectomy, history of bilateral tubal ligation, or history of bilateral oophorectomy) OR must have a negative urine or serum pregnancy within 72 hours prior to receiving the first dose of study treatment; if the urine test is positive or cannot be confirmed as negative, a serum pregnancy test will be required; subjects with a negative pregnancy test at screening beyond 72 hours prior to treatment, but who otherwise meet all other criteria, may be registered to trial but must have a repeat negative serum pregnancy test within 72 hours of treatment and such testing may be done on day of first treatment prior to administrationXx_NEWLINE_xXFemale subjects of childbearing potential should have a negative urine or serum pregnancy test within 72 hours prior to receiving the first dose of study medication; if the urine test is positive or cannot be confirmed as negative, a serum pregnancy test will be requiredXx_NEWLINE_xXFemale participants of childbearing potential must have a negative serum pregnancy test within 72 hours prior to receiving the first dose of study therapyXx_NEWLINE_xXHave a negative result confirmed for a medically supervised urine (or serum) pregnancy test (with a sensitivity of at least 25 mIU/mL) 10-14 days prior to the first dose of IP. A second pregnancy test performed within 24 hours prior to the first dose of IP must also be confirmed to be negative prior to IP administration.Xx_NEWLINE_xXWomen of childbearing potential (WOCBP) must have a negative urine or serum pregnancy test at screening and =< 72 hours prior to day 1 of study treatment; if the urine pregnancy test is positive or cannot be confirmed as negative, a serum pregnancy test will be required\r\n* A woman of childbearing potential is a sexually mature female who: has not undergone a hysterectomy or bilateral oophorectomy; or has not been naturally postmenopausal for at least 24 consecutive months (i.e. has had menses at any time in the preceding 24 consecutive months).Xx_NEWLINE_xXWomen of childbearing potential (WOCBP): negative urine or serum pregnancy test; if the urine test is positive or cannot be confirmed as negative, a serum pregnancy test will be requiredXx_NEWLINE_xXFemale subject of childbearing potential should have a negative urine or serum pregnancy within 72 hours prior to receiving the first dose of study medication; if the urine test is positive or cannot be confirmed as negative, a serum pregnancy test will be requiredXx_NEWLINE_xXFemale subjects of childbearing potential should have a negative urine or serum pregnancy test within 14 days of treatment registration; female subjects of childbearing potential should have a negative urine or serum pregnancy test repeated within 72 hours prior to receiving the first dose of study medication; if the urine test is positive or cannot be confirmed as negative, a serum pregnancy test will be requiredXx_NEWLINE_xXWomen of childbearing potential (WOCP) must not be pregnant or breast-feeding. A negative serum or urine pregnancy test is required within 72 hours of study registration. If the urine test cannot be confirmed as negative, a serum pregnancy test will be required.Xx_NEWLINE_xXFemale participants of childbearing potential should have a negative urine or serum pregnancy test within 72 hours prior to receiving the first dose of study medicationXx_NEWLINE_xXAnd have a negative serum pregnancy test at screeningXx_NEWLINE_xXFemale subject of childbearing potential should have a negative urine or serum pregnancy test within 7 days prior to receiving the first dose of study medication; if the urine test is positive or cannot be confirmed as negative, a serum pregnancy test will be requiredXx_NEWLINE_xXFemales of childbearing potential must have a negative serum or urine pregnancy test within 72 hours prior to start of first cycle of therapyXx_NEWLINE_xXFOCBP must have a negative serum or urine pregnancy test within 14 days prior to registration on studyXx_NEWLINE_xXWomen of childbearing potential (i.e., menstruating women) must have a negative urine pregnancy test (positive urine tests are to be confirmed by serum test) documented within the 24-hour period prior to the first dose of study drug.Xx_NEWLINE_xXFemale subject of childbearing potential should have a negative urine or serum pregnancy within 72 hours prior to receiving the first dose of study medication; if the urine test is positive or cannot be confirmed as negative, a serum pregnancy test will be requiredXx_NEWLINE_xXFemale patient of childbearing potential has a negative serum or urine pregnancy within 72 hours prior to receiving the first dose of study medicationXx_NEWLINE_xXFemale subject of childbearing potential should have a negative urine or serum pregnancy within 72 hours prior to receiving the first dose of HiDAC treatment and again prior to D1 of pembrolizumab treatment; if the urine test is positive or cannot be confirmed as negative, a serum pregnancy test will be requiredXx_NEWLINE_xXFemale subjects must have a negative urine or serum pregnancy test within 72 hours prior to start of study treatment if of childbearing potential or be of non-childbearing potential; if the urine test is positive or cannot be confirmed as negative, a serum pregnancy test will be required; the serum pregnancy test must be negative for the subject to be eligible; non-childbearing potential is defined as:\r\n* >= 45 years of age and has not had menses for > 2 years\r\n* Amenorrheic for > 2 years without a hysterectomy and oophorectomy and a follicle stimulating hormone (FSH) value in the postmenopausal range upon pretrial (screening) evaluation \r\n* Post-hysterectomy, oophorectomy, or tubal ligation; documented hysterectomy or oophorectomy must be confirmed with medical records of the actual procedure or confirmed by an ultrasound; tubal ligation must be confirmed with medical records of the actual procedureXx_NEWLINE_xXFemale subject of childbearing potential should have a negative urine or serum pregnancy within 72 hours prior to receiving the first dose of study medication; if the urine test is positive or cannot be confirmed as negative, a serum pregnancy test will be requiredXx_NEWLINE_xXFemale subject of childbearing potential should have a negative urine or serum pregnancy test within 28 days of study registration; if the urine test is positive or cannot be confirmed as negative, a serum pregnancy test will be requiredXx_NEWLINE_xXPregnant and/or breastfeeding; a negative serum or urine pregnancy test is required at screening for all female patients of childbearing potentialXx_NEWLINE_xXFemale subjects of childbearing potential must not be pregnant or breast-feeding; female patients of childbearing potential must have a negative serum or urine pregnancy test within 72 hours prior to receiving the first dose of study medication; if the urine test is positive or cannot be confirmed as negative, a serum pregnancy test will be required; pregnant women are excluded from this study; breastfeeding should be discontinued if the mother is to be treated with MK-3475 (pembrolizumab)Xx_NEWLINE_xXINCLUSION CRITERIA FOR STRATUM C: Female subjects of childbearing potential must not be pregnant or breast-feeding; female patients of childbearing potential must have a negative serum or urine pregnancy test within 72 hours prior to receiving the first dose of study medication; if the urine test is positive or cannot be confirmed as negative, a serum pregnancy test will be required; pregnant women are excluded from this study; breastfeeding should be discontinued if the mother is to be treated with MK-3475 (pembrolizumab)Xx_NEWLINE_xXPregnant and/or breastfeeding; patient must have a negative serum or urine pregnancy test within 2 weeks of study entryXx_NEWLINE_xXPregnant and/or breastfeeding; patient must have a negative serum or urine pregnancy test within 72 hours of study entryXx_NEWLINE_xXNegative serum pregnancy testXx_NEWLINE_xXNegative urine or serum pregnancy test for females of childbearing potentialXx_NEWLINE_xXFemale subject of childbearing potential should have a negative serum pregnancy within 72 hours prior to receiving the first dose of study medication.Xx_NEWLINE_xXNegative serum or urine pregnancy test for women within 72 hours of receiving the first dose of the study medication for women of childbearing potential.Xx_NEWLINE_xXFemale participants of childbearing potential must have a negative urine or serum pregnancy test within 72 hours prior to receiving the first dose of study medication. If the urine test is positive or cannot be confirmed as negative, a serum pregnancy test will be required.Xx_NEWLINE_xXFemale subjects of childbearing potential should have a negative urine or serum pregnancy within 72 hours prior to receiving the first dose of study medication; if the urine test is positive or cannot be confirmed as negative, a serum pregnancy test will be required.Xx_NEWLINE_xXFemale patients of childbearing potential must have a negative pregnancy test, as measured by serum or urine testingXx_NEWLINE_xXPregnant or lactating (female participant of childbearing potential must have negative serum or urine pregnancy test required within 7 days prior to start of treatment)Xx_NEWLINE_xXFemale participants of childbearing potential must have a negative serum pregnancy within 72 hours prior to enrollmentXx_NEWLINE_xXFemale subject of childbearing potential should have a negative urine or serum pregnancy within 72 hours prior to receiving the first dose of study medication; if the urine test is positive or cannot be confirmed as negative, a serum pregnancy test will be requiredXx_NEWLINE_xXFemale subject of childbearing potential should have a negative urine or serum pregnancy test within 72 hours prior to receiving the first dose of study medication; if the urine test is positive or cannot be confirmed as negative, a serum pregnancy test will be requiredXx_NEWLINE_xXFemale subject of childbearing potential should have a negative urine or serum pregnancy within 72 hours prior to receiving the first dose of study medication; if the urine test is positive or cannot be confirmed as negative, a serum pregnancy test will be requiredXx_NEWLINE_xXFemale of childbearing potential: negative urine or serum pregnancy test, performed within 14 days prior to day 1 of protocol therapy\r\n* If the urine test is positive or cannot be confirmed as negative, a serum pregnancy test will be requiredXx_NEWLINE_xXFemale subject of childbearing potential should have a negative urine or serum pregnancy within 72 hours prior to receiving the first dose of study medication; if the urine test is positive or cannot be confirmed as negative, a serum pregnancy test will be requiredXx_NEWLINE_xXFemale subject of childbearing potential should have a negative urine or serum pregnancy prior to receiving the first dose of study medication; if the urine test is positive or cannot be confirmed as negative, a serum pregnancy test will be requiredXx_NEWLINE_xXFor female subjects of childbearing potential, a negative urine or serum pregnancy test prior to the start of study therapy.Xx_NEWLINE_xXFemale subject of childbearing potential should have a negative urine or serum pregnancy within 72 hours prior to receiving the first dose of study medication; if the urine test is positive or cannot be confirmed as negative, a serum pregnancy test will be requiredXx_NEWLINE_xXFemale subject of childbearing potential should have a negative urine or serum pregnancy test within 72 hours prior to receiving the first dose of study drug. If the urine test is positive, a serum pregnancy test will be requiredXx_NEWLINE_xXWOCBP who has a positive urine pregnancy test within 72 hours before the first dose of study treatmentXx_NEWLINE_xXFemale subject of childbearing potential should have a negative urine or serum pregnancy within 72 hours prior to receiving the first dose of study medication; if the urine test is positive or cannot be confirmed as negative, a serum pregnancy test will be requiredXx_NEWLINE_xXFemales must be surgically or biologically sterile or postmenopausal (amenorrheic for at least 12 months) or if of childbearing potential, must have a negative serum or urine pregnancy test within 72 hours before the start of the treatmentXx_NEWLINE_xXFemale subject of childbearing potential should have a negative urine or serum pregnancy within 72 hours prior to receiving the first dose of study medication; if the urine test is positive or cannot be confirmed as negative, a serum pregnancy test will be requiredXx_NEWLINE_xXWomen of childbearing potential should have a negative urine or serum pregnancy within 72 hours prior to receiving the first dose of study drug; if the urine test is positive or cannot be confirmed as negative, a serum pregnancy test will be requiredXx_NEWLINE_xXFemale subject of childbearing potential should have a negative urine or serum pregnancy within 72 hours prior to receiving the first dose of study medication; if the urine test is positive or cannot be confirmed as negative, a serum pregnancy test will be requiredXx_NEWLINE_xXFemale subject of childbearing potential should have a negative urine or serum pregnancy within 72 hours prior to receiving the first dose of study medication. If the urine test is positive or cannot be confirmed as negative, a serum pregnancy test will be required.Xx_NEWLINE_xXFemales must be surgically or biologically sterile or postmenopausal (amenorrheic for at least 12 months) or if of childbearing potential, must have a negative serum or urine pregnancy test within 72 hours before the start of the treatment.Xx_NEWLINE_xXNegative serum pregnancy test at screeningXx_NEWLINE_xXFemale patients of childbearing potential should have a negative urine or serum pregnancy within 72 hours before receiving the first dose of study medication; if the urine test is positive or cannot be confirmed as negative, a serum pregnancy test will be requiredXx_NEWLINE_xXFemale subject of childbearing potential should have a negative urine or serum pregnancy within 72 hours prior to receiving the first dose of study medication; if the urine test is positive or cannot be confirmed as negative, a serum pregnancy test will be requiredXx_NEWLINE_xXFemale subjects of childbearing potential should have a negative urine or serum pregnancy test within 72 hours prior to receiving the first dose of study medication and agree to use effective contraception; if the urine test is positive or cannot be confirmed as negative, a serum pregnancy test will be required; Note: Abstinence is acceptable if this is the usual lifestyle and preferred contraception for the subjectXx_NEWLINE_xXFemale subject of childbearing potential should have a negative urine or serum pregnancy within 72 hours prior to receiving the first dose of study medication; if the urine test is positive or cannot be confirmed as negative, a serum pregnancy test will be requiredXx_NEWLINE_xXFemale subjects of childbearing potential should have a negative urine or serum pregnancy within 72 hours prior to receiving the first dose of study medication; if the urine test is positive or cannot be confirmed as negative, a serum pregnancy test will be requiredXx_NEWLINE_xXFemale participants of childbearing potential should have a negative serum pregnancy test within 24 hours prior to receiving first dose of trial medication.Xx_NEWLINE_xXFemale patients of childbearing potential must have a negative urine or serum pregnancy test confirmed prior to enrollmentXx_NEWLINE_xXFemale subject of childbearing potential should have a negative urine or serum pregnancy within 72 hours prior to receiving the first dose of study medication; if the urine test is positive or cannot be confirmed as negative, a serum pregnancy test will be requiredXx_NEWLINE_xXFemale subject of childbearing potential should have a negative urine or serum pregnancy within 72 hours prior to receiving the first dose of study medication. If the urine test is positive or cannot be confirmed as negative, a serum pregnancy test will be required.Xx_NEWLINE_xXFemale subject of childbearing potential should have a negative urine or serum pregnancy within 72 hours prior to receiving the first dose of study medication; if the urine test is positive or cannot be confirmed as negative, a serum pregnancy test will be requiredXx_NEWLINE_xXFemale subject of childbearing potential should have a negative urine or serum pregnancy within 72 hours prior to receiving the first dose of DCBA; if the urine test is positive or cannot be confirmed as negative, a serum pregnancy test will be requiredXx_NEWLINE_xXFemale subject of childbearing potential should have a negative urine or serum pregnancy within 72 hours prior to receiving the first dose of study medication. If the urine test is positive or cannot be confirmed as negative, a serum pregnancy test will be required.Xx_NEWLINE_xXFemale subject of childbearing potential should have a negative urine or serum pregnancy within 72 hours prior to receiving the first dose of study medication. If the urine test is positive or cannot be confirmed as negative, a serum pregnancy test will be requiredXx_NEWLINE_xXFemale subject of childbearing potential should have a negative serum pregnancy within 72 hours prior to receiving the first dose of study medicationXx_NEWLINE_xXFemale subject of childbearing potential should have a negative urine or serum pregnancy within 72 hours prior to receiving the first dose of study medication; if the urine test is positive or cannot be confirmed as negative, a serum pregnancy test will be requiredXx_NEWLINE_xXhave a negative serum pregnancy test at the time of enrollment,Xx_NEWLINE_xXhave a negative urine pregnancy test within 24 hours prior to the first dose of study treatment, andXx_NEWLINE_xXFemale subject of childbearing potential should have a negative urine or serum pregnancy prior to receiving the first dose of study medication; if the urine test is positive or cannot be confirmed as negative, a serum pregnancy test will be requiredXx_NEWLINE_xXFemale subject of childbearing potential should have a negative urine or serum pregnancy within 72 hours prior to receiving the first dose of study medication. If the urine test is positive or cannot be confirmed as negative, a serum pregnancy test will be required.Xx_NEWLINE_xXFemale subject of childbearing potential should have a negative urine or serum pregnancy test within 72 hours prior to receiving the first dose of study medication; if the urine test is positive or cannot be confirmed as negative, a serum pregnancy test will be requiredXx_NEWLINE_xXNegative urine or serum pregnancy test done =< 72 hours prior to first treatment, for women of childbearing potential only\r\n* If the urine test is positive or cannot be confirmed as negative, a serum pregnancy test will be requiredXx_NEWLINE_xXFemale subject of childbearing potential should have a negative urine or serum pregnancy prior to receiving the first study treatment; if the urine test is positive or cannot be confirmed as negative, a serum pregnancy test will be requiredXx_NEWLINE_xXFemale patients of childbearing potential should have a negative pregnancy test within 10 days prior to on-study date; if a urine or serum test is positive or cannot be confirmed as negative, the other (urine or serum pregnancy test, whichever was not performed first) will be requiredXx_NEWLINE_xXFemales of childbearing potential must have a negative pregnancy test within 10 days prior to “on study” status; if a urine or serum test is positive or cannot be confirmed as negative, the other (urine or serum pregnancy test, whichever was not performed first) will be requiredXx_NEWLINE_xXHave a negative urine or serum pregnancy test within 72 hours prior to receiving the first dose of study medication (cycle 1, day 1) (female subjects of childbearing potential); if the urine test is positive or cannot be confirmed as negative, a serum pregnancy test will be requiredXx_NEWLINE_xXWomen of childbearing potential must have a negative serum or urine pregnancy test within 72 hours prior to the first dose of pembrolizumabXx_NEWLINE_xXFemale subjects of childbearing potential as defined in Section 5.7.2 must have a negative urine or serum pregnancy within 72 hours prior to receiving the first dose of study medication. If the urine test is positive or cannot be confirmed as negative, a serum pregnancy test will be required.Xx_NEWLINE_xXFemale subjects of childbearing potential should have a negative urine or serum pregnancy within 72 hours prior to receiving the first dose of study medication; if the urine test is positive or cannot be confirmed as negative, a serum pregnancy test will be requiredXx_NEWLINE_xXFemale subject of childbearing potential should have a negative urine or serum pregnancy within 72 hours prior to receiving the first dose of study medication or study indicated ultrasound treatment; if the urine test is positive or cannot be confirmed as negative, a serum pregnancy test will be requiredXx_NEWLINE_xXFemale subject of childbearing potential should have a negative urine or serum pregnancy within 72 hours prior to receiving the first dose of study medication. If the urine test is positive or cannot be confirmed as negative, a serum pregnancy test will be required. Female and male subjects of childbearing potential must be willing to use an adequate method of contraception for the course of the study through 120 days after the last dose of study medication. Note: abstinence is acceptable if this is the usual lifestyle and preferred contraception for the subjectXx_NEWLINE_xXFemale subject of childbearing potential should have a negative urine or serum pregnancy within 24 hours prior to receiving the first dose of study medication; if the urine test is positive or cannot be confirmed as negative, a serum pregnancy test will be requiredXx_NEWLINE_xXFemale subject of childbearing potential should have a negative urine or serum pregnancy within 72 hours prior to receiving the first dose of study medication; if the urine test is positive or cannot be confirmed as negative, a serum pregnancy test will be requiredXx_NEWLINE_xXFemale subject of childbearing potential should have a negative urine or serum pregnancy within 72 hours prior to receiving the first dose of study medication. If the urine test is positive or cannot be confirmed as negative, a serum pregnancy test will be requiredXx_NEWLINE_xXNegative urine or serum pregnancy within 72 hours prior to receiving the first dose of study medication for female subjects of childbearing ageXx_NEWLINE_xXNegative pregnancy test done =< 7 days prior to registration, for persons of childbearing potential only (POCBP)\r\n* NOTE: Serum or urine pregnancy test allowed; if urine test is positive or cannot be confirmed as negative, a serum pregnancy test will be requiredXx_NEWLINE_xXFemale subject of childbearing potential should have a negative urine or serum pregnancy within 3 days prior to receiving the first dose of study medication; if the urine test is positive or cannot be confirmed as negative, a serum pregnancy test will be requiredXx_NEWLINE_xXFemale subject of childbearing potential should have a negative urine or serum pregnancy within 72 hours prior to receiving the first dose of study medication; if the urine test is positive or cannot be confirmed as negative, a serum pregnancy test will be requiredXx_NEWLINE_xXFemale patients of childbearing potential must have a negative pregnancy test (either urine or serum pregnancy test) within 72 hours prior to the first dose of study treatment. If the urine test is positive or cannot be confirmed as negative, a serum pregnancy test will be required.Xx_NEWLINE_xXNegative urine or serum pregnancy test in females. Male and female patients with reproductive potential must use an approved contraceptive method if appropriateXx_NEWLINE_xXSTUDY TREATMENT: Female subject of childbearing potential should have a negative urine or serum pregnancy within 72 hours prior to receiving the first dose of study medication; if the urine test is positive or cannot be confirmed as negative, a serum pregnancy test will be requiredXx_NEWLINE_xXFemale subject of childbearing potential should have a negative urine or serum pregnancy within 72 hours prior to receiving the first dose of study medication; if the urine test is positive or cannot be confirmed as negative, a serum pregnancy test will be requiredXx_NEWLINE_xXFor women of childbearing potential, a negative serum or urine pregnancy test with sensitivity less than 50 mIU/m within 72 hours before the start of study medicationXx_NEWLINE_xXFemale subject of childbearing potential should have a negative urine or serum pregnancy within 72 hours prior to receiving the first dose of study medication; if the urine test is positive or cannot be confirmed as negative, a serum pregnancy test will be requiredXx_NEWLINE_xXFemale subject of childbearing potential should have a negative urine or serum pregnancy within 72 hours prior to receiving the first dose of study medication; if the urine test is positive or cannot be confirmed as negative, a serum pregnancy test will be requiredXx_NEWLINE_xXNegative serum pregnancy test.Xx_NEWLINE_xXFemale subject of childbearing potential should have a negative urine or serum pregnancy within 72 hours prior to receiving the first dose of study medication. If the urine test is positive or cannot be confirmed as negative, a serum pregnancy test will be requiredXx_NEWLINE_xXFemale patient of childbearing potential has a negative serum or urine pregnancy within 72 hours prior to receiving the first dose of study medicationXx_NEWLINE_xXFemale subject of childbearing potential should have a negative urine or serum pregnancy within 72 hours prior to receiving the first dose of study medication; if the urine test is positive or cannot be confirmed as negative, a serum pregnancy test will be requiredXx_NEWLINE_xXFOCBP must have a negative serum OR urine pregnancy test =< 7 days prior to registrationXx_NEWLINE_xXFemale subject of childbearing potential should have a negative serum pregnancy testing at screening visit and within 72 hours prior to the first dose of study medicationXx_NEWLINE_xXHas a negative serum pregnancy test within 7 days prior to starting treatment.Xx_NEWLINE_xXFemale subject of childbearing potential should have a negative urine or serum pregnancy within 72 hours prior to receiving the first dose of study medication; if the urine test is positive or cannot be confirmed as negative, a serum pregnancy test will be requiredXx_NEWLINE_xXFemale subject of childbearing potential should have a negative serum pregnancy within 48 hours prior to receiving the first dose of study medicationXx_NEWLINE_xXFemale subject of childbearing potential should have a negative urine or serum pregnancy within 72 hours prior to receiving the first dose of study medication; if the urine test is positive or cannot be confirmed as negative, a serum pregnancy test will be requiredXx_NEWLINE_xXFemale patient of childbearing potential has a negative urine or serum pregnancy test; if the urine test is positive or cannot be confirmed as negative, a serum pregnancy test will be required; the serum pregnancy test must be negative for the patient to be eligibleXx_NEWLINE_xXFemale subject of childbearing potential should have a negative urine or serum pregnancy within 72 hours prior to receiving the first dose of study medication; if the urine test is positive or cannot be confirmed as negative, a serum pregnancy test will be requiredXx_NEWLINE_xXNegative serum pregnancy test for women of childbearing potential =< 7 days prior to registration; Note: a second pregnancy test may be required =< 72 hours prior to receiving the first dose of study medicationXx_NEWLINE_xXFemale subject of childbearing potential should have a negative urine or serum pregnancy within 72 hours prior to receiving the first dose of study medication; if the urine test is positive or cannot be confirmed as negative, a serum pregnancy test will be requiredXx_NEWLINE_xXFOCBP must have a negative pregnancy test (either urine or serum) within 14 days prior to registrationXx_NEWLINE_xXFemale subject of childbearing potential should have a negative urine or serum pregnancy; if the urine test is positive or cannot be confirmed as negative, a serum pregnancy test will be requiredXx_NEWLINE_xXFemale subjects of childbearing potential should have a negative urine or serum pregnancy within 7 days prior to receiving the first dose of study medication; if the urine test is positive or cannot be confirmed as negative, a negative serum pregnancy test will be requiredXx_NEWLINE_xXFemale subject of childbearing potential should have a negative urine or serum pregnancy at screening and within 24 hours prior to receiving the first dose of study medication; if the urine test is positive or cannot be confirmed as negative, a serum pregnancy test will be requiredXx_NEWLINE_xXTo be performed within 10 business days prior to day 1: Female of childbearing potential: negative urine or serum pregnancy test; if the urine test is positive or cannot be confirmed as negative, a serum pregnancy test will be requiredXx_NEWLINE_xXWithin 14 days prior to planned start of treatment: Female of childbearing potential: negative urine or serum pregnancy test\r\n* If the urine test is positive or cannot be confirmed as negative, a serum pregnancy test will be requiredXx_NEWLINE_xXFor WoCBP* negative serum pregnancy test within 7 days of enrollment.Xx_NEWLINE_xXFemale subject of childbearing potential should have a negative urine or serum pregnancy within 72 hours prior to receiving the first dose of study medication; if the urine test is positive or cannot be confirmed as negative, a serum pregnancy test will be requiredXx_NEWLINE_xXFemale subject of childbearing potential should have a negative urine or serum pregnancy within 72 hours prior to receiving the first dose of study medication; if the urine test is positive or cannot be confirmed as negative, a serum pregnancy test will be requiredXx_NEWLINE_xXWomen of childbearing potential also may not be breast feeding and must have a negative serum or urine pregnancy test within 72 hours before the start of study treatmentXx_NEWLINE_xXFemale subject of childbearing potential should have a negative urine or serum pregnancy within 72 hours prior to receiving the first dose of study medication; if the urine test is positive or cannot be confirmed as negative, a serum pregnancy test will be requiredXx_NEWLINE_xXFemale subject of childbearing potential should have a negative urine or serum pregnancy within 72 hours prior to receiving the first dose of study medication; if the urine test is positive or cannot be confirmed as negative, a serum pregnancy test will be requiredXx_NEWLINE_xXFemale subject of childbearing potential should have a negative urine or serum pregnancy within 72 hours prior to receiving the first dose of study medication; if the urine test is positive or cannot be confirmed as negative, a serum pregnancy test will be requiredXx_NEWLINE_xXHas negative serum or urine pregnancy test for subjects of childbearing potential within 10 days before first dose.Xx_NEWLINE_xXFemale subject of childbearing potential should have a negative urine or serum pregnancy within 72 hours prior to receiving the first dose of study medication; if the urine test is positive or cannot be confirmed as negative, a serum pregnancy test will be requiredXx_NEWLINE_xXFemale subjects of childbearing potential must have a negative urine or serum pregnancy within 72 hours prior to receiving the first dose of study medication; if the urine test is positive or cannot be confirmed as negative, a serum pregnancy test will be requiredXx_NEWLINE_xXFemale subject of childbearing potential should have a negative urine or serum pregnancy within 72 hours prior to receiving the first dose of study medication; if the urine test is positive or cannot be confirmed as negative, a serum pregnancy test will be requiredXx_NEWLINE_xXFemales must be surgically or biologically sterile or postmenopausal (amenorrheic for at least 12 months) or if of childbearing potential, must have a negative serum or urine pregnancy test within 72 hours before the start of the treatmentXx_NEWLINE_xXFemale subject of childbearing potential should have a negative urine or serum pregnancy within 72 hours prior to receiving the first dose of study medication; if the urine test is positive or cannot be confirmed as negative, a serum pregnancy test will be requiredXx_NEWLINE_xXHave a negative urine or serum pregnancy test within 72 hours prior to receiving the first dose of study medication (cycle 1, day 1) (female subjects of childbearing potential); if the urine test is positive or cannot be confirmed as negative, a serum pregnancy test will be requiredXx_NEWLINE_xXA negative urine dipstick pregnancy testXx_NEWLINE_xXHave a negative urine or serum pregnancy test within 72 hours prior to receiving the first dose of study medication, pembrolizumab (cycle 1, day 1) (female subjects of childbearing potential); if the urine test is positive or cannot be confirmed as negative, a serum pregnancy test will be requiredXx_NEWLINE_xXFemale subject of childbearing potential should have a negative urine or serum pregnancy within 72 hours prior to receiving the first dose of study medication; if the urine test is positive or cannot be confirmed as negative, a serum pregnancy test will be requiredXx_NEWLINE_xXWomen of childbearing potential must have a negative serum or urine pregnancy test within 72 hours prior to the start of nivolumabXx_NEWLINE_xXHave a negative urine or serum pregnancy test within 72 hours prior to receiving the first dose of study medication (cycle 1, day 1) (female subjects of childbearing potential); if the urine test is positive or cannot be confirmed as negative, a serum pregnancy test will be requiredXx_NEWLINE_xXFemale subject of childbearing potential should have a negative urine or serum pregnancy within 72 hours prior to receiving the first dose of study medication; if the urine test is positive or cannot be confirmed as negative, a serum pregnancy test will be requiredXx_NEWLINE_xXNegative serum pregnancy within 72 hours prior to receiving the first dose of study medication (unless surgically sterile or postmenopausal for greater than one year)Xx_NEWLINE_xXFemale subject of childbearing potential has a negative urine or serum pregnancy test; if the urine test is positive or cannot be confirmed as negative, a serum pregnancy test will be required; the serum pregnancy test must be negative for the subject to be eligibleXx_NEWLINE_xXFemale subjects of childbearing potential should have a negative urine or serum pregnancy within 72 hours prior to receiving the first dose of study medication; if the urine test is positive or cannot be confirmed as negative, a serum pregnancy test will be requiredXx_NEWLINE_xXParticipants of childbearing potential must have a negative urine or serum pregnancy within 72 hours prior to receiving the first dose of study medication; if the urine test is positive or cannot be confirmed as negative, a serum pregnancy test will be requiredXx_NEWLINE_xXFemale subject of childbearing potential should have a negative urine or serum pregnancy test within 10 days of initiating SBRT; if the urine test is positive or cannot be confirmed as negative, a serum pregnancy test will be requiredXx_NEWLINE_xXNegative urine or serum pregnancy test (female of childbearing potential only)\r\n* If the urine test is positive or cannot be confirmed as negative, a serum pregnancy test will be requiredXx_NEWLINE_xXNegative serum pregnancy testXx_NEWLINE_xXFemales of child-bearing potential (not surgically sterilized or postmenopausal [a woman who is >= 45 years of age and has not had menses for greater than 1 year]) must test negative for pregnancy within 48 hours prior to any initial study procedure based on a serum pregnancy test; both sexually active males and females of reproductive potential must agree to use a reliable method of birth control, as determined by the patient and their health care team, during the study and for 120 days following the last dose of study drug; if subject uses appropriate contraceptive methods (the use of two forms at the same time) from the time of the initial serum pregnancy test, then the subsequent pregnancy test can be done within 72 hours of receiving study drug administration; if appropriate; contraceptive measures are not begun immediately with the first serum pregnancy test, then subsequent serum pregnancy tests must be done within 48 hours prior to the study drug administrationXx_NEWLINE_xXFemale subject of childbearing potential should have a negative urine or serum pregnancy within 72 hours prior to receiving the first dose of study medication; if the urine test is positive or cannot be confirmed as negative, a serum pregnancy test will be requiredXx_NEWLINE_xXFOCBP must have a negative urine or serum pregnancy test within 7 days prior to receiving the first dose of study medication; if the urine test is positive or cannot be confirmed as negative, a serum pregnancy test will be requiredXx_NEWLINE_xXFOCBP must have a negative pregnancy test (serum or urine) within 7 days prior to registration on studyXx_NEWLINE_xXDONOR: Not pregnant as confirmed by negative serum or urine pregnancy test within 14 days prior to enrollment (if female)Xx_NEWLINE_xXFemale subjects of childbearing potential should have a negative urine or serum pregnancy within 72 hours prior to receiving the first dose of study medication; if the urine test is positive or cannot be confirmed as negative, a serum pregnancy test will be requiredXx_NEWLINE_xXWomen of childbearing potential must have a negative serum or urine pregnancy test within 72 hours prior to start of IRX5183Xx_NEWLINE_xXPatients of childbearing potential must have a negative urine or serum pregnancy test =< 7 days prior to registration\r\n* NOTE: If the urine test is positive or cannot be confirmed as negative, a serum pregnancy test will be requiredXx_NEWLINE_xXFemale subjects of childbearing potential should have a negative urine or serum pregnancy within 72 hours prior to receiving the first dose of study medication; if the urine test is positive or cannot be confirmed as negative, a serum pregnancy test will be requiredXx_NEWLINE_xXFemale subject of childbearing potential should have a negative urine or serum pregnancy within 72 hours prior to receiving the first dose of study medication; if the urine test is positive or cannot be confirmed as negative, a serum pregnancy test will be requiredXx_NEWLINE_xXFemale subject of childbearing potential should have a negative urine or serum pregnancy within 72 hours prior to receiving the first dose of study medication; if the urine test is positive or cannot be confirmed as negative, a serum pregnancy test will be requiredXx_NEWLINE_xXFemale subject of childbearing potential should have a negative urine or serum pregnancy within 28 days prior to study registration up to the first fraction of radiation; \r\n* Note: if the urine test is positive or cannot be confirmed as negative, a serum pregnancy test will be requiredXx_NEWLINE_xXFemale subject of childbearing potential require a negative pregnancy test within 72 hours prior to receiving the first dose of study medication; if the urine test is positive or cannot be confirmed as negative, a serum pregnancy test will be requiredXx_NEWLINE_xXFemale subjects of childbearing potential should have a negative urine or serum pregnancy within 72 hours prior to receiving the first dose of study medication; if the urine test is positive or cannot be confirmed as negative, a serum pregnancy test will be requiredXx_NEWLINE_xXFemale subject of childbearing potential should have a negative urine or serum pregnancy within 24 hours of study enrollment up to administration of the dose of study drug; if the urine test is positive or cannot be confirmed as negative, a serum pregnancy test will be requiredXx_NEWLINE_xXFemale subjects of childbearing potential should have a negative urine or serum pregnancy within 72 hours prior to receiving the first dose of pembrolizumab; if the urine test is positive or cannot be confirmed as negative, a serum pregnancy test will be requiredXx_NEWLINE_xXPRIOR TO LYMPHODEPLETION: For WOCBP negative serum pregnancy test within 72 hours prior to lymphodepletionXx_NEWLINE_xXFemale subject of childbearing potential should have a negative urine or serum pregnancy within 72 hours prior to receiving the first dose of study medication; if the urine test is positive or cannot be confirmed as negative, a serum pregnancy test will be requiredXx_NEWLINE_xXNegative serum or urine pregnancy test for women with reproductive potentialXx_NEWLINE_xXFemale subject of childbearing potential should have a negative urine or serum pregnancy within 72 hours prior to receiving the first dose of study medication; if the urine test is positive or cannot be confirmed as negative, a serum pregnancy test will be requiredXx_NEWLINE_xXFemale subjects of childbearing potential should have a negative serum pregnancy test within 72 hours prior to receiving first dose of study medication; if the urine test is positive or cannot be confirmed as negative, a serum pregnancy test will be requiredXx_NEWLINE_xXFemale subject of childbearing potential should have a negative urine or serum pregnancy within 72 hours of study enrollment; if the urine test is positive or cannot be confirmed as negative, a serum pregnancy test will be requiredXx_NEWLINE_xXhave a negative serum pregnancy test at screening and before Betalutin injectionXx_NEWLINE_xXFemale subject of childbearing potential should have a negative urine or serum pregnancy within 72 hours prior to receiving the first dose of study medication; if the urine test is positive or cannot be confirmed as negative, a serum pregnancy test will be requiredXx_NEWLINE_xXPregnancy or breast-feeding; female patients must be surgically sterile or be postmenopausal for two years, or must agree to use effective contraception during the period of treatment and 6 months after; all female patients with reproductive potential must have a negative pregnancy test (serum/urine) within 48 hours from starting the conditioning chemotherapyXx_NEWLINE_xXFemale patient of childbearing potential (WOCBP) (free from menses for > 2 years, post hysterectomy/oophorectomy, or surgically sterilized) must have a negative urine or serum pregnancy test; if the urine test is positive or cannot be confirmed as negative a serum pregnancy test will be required to be shown as negative for the patient to be eligibleXx_NEWLINE_xXPregnant or lactating women; female study participants of reproductive potential must have a negative serum or urine pregnancy test performed within 48 hours before infusionXx_NEWLINE_xXDONOR: Female subjects must have a negative urine or serum pregnancy test within 10 days prior to taking study medication if of childbearing potential or must be of non-childbearing potential; if the urine test is positive or cannot be confirmed as negative, a serum pregnancy test will be required; the serum pregnancy test must be negative for the subject to be eligible; non-childbearing potential is defined as:\r\n* >= 45 years of age and has not had menses for > 2 years\r\n* Amenorrheic for > 2 years without a hysterectomy and oophorectomy and a follicle-stimulating hormone (FSH) value in the postmenopausal range upon pretrial (screening) evaluation\r\n* Post-hysterectomy, oophorectomy, or tubal ligationXx_NEWLINE_xXFemale subjects must have a negative urine or serum pregnancy test if of childbearing potential or be of non-childbearing potential; if the urine test is positive or cannot be confirmed as negative, a serum pregnancy test will be required; the serum pregnancy test must be negative for the subject to be eligible; non-childbearing potential is defined as:\r\n* >= 45 years of age and has not had menses for > 2 years\r\n* Amenorrheic for > 2 years without a hysterectomy and oophorectomy and a FSH value in the postmenopausal range upon pretrial (screening) evaluation\r\n* Post-hysterectomy, oophorectomy, or tubal ligationXx_NEWLINE_xXFemale subjects of childbearing potential should have a negative urine or serum pregnancy within 72 hours prior to receiving the first dose of study medication; if the urine test is positive or cannot be confirmed as negative, a serum pregnancy test will be requiredXx_NEWLINE_xXPregnant and/or breastfeeding; patient must have a negative serum or urine pregnancy test within 72 hours of study entryXx_NEWLINE_xXFemale subject of childbearing potential should have a negative urine or serum pregnancy within 72 hours prior to receiving the first dose of study medication; if the urine test is positive or cannot be confirmed as negative, a serum pregnancy test will be requiredXx_NEWLINE_xXNegative serum or urine pregnancy test for women within 72 hours of receiving the first dose of the study medication for women of childbearing potentialXx_NEWLINE_xXFemale subject of childbearing potential should have a negative urine or serum pregnancy within 72 hours prior to receiving the first dose of study medication. If the urine test is positive or cannot be confirmed as negative, a serum pregnancy test will be required.Xx_NEWLINE_xXFemale subject of childbearing potential should have a negative urine or serum pregnancy within 72 hours prior to receiving the first dose of study medication; if the urine test is positive or cannot be confirmed as negative, a serum pregnancy test will be requiredXx_NEWLINE_xXFemales of childbearing potential must have negative serum or urine pregnancy test.Xx_NEWLINE_xXFemale subject of childbearing potential should have a negative urine or serum pregnancy within 72 hours prior to receiving the first dose of study medication; if the urine test is positive or cannot be confirmed as negative, a serum pregnancy test will be requiredXx_NEWLINE_xXNegative serum or urine pregnancy test for women within 72 hours of receiving the first dose of the study medication for women of childbearing potentialXx_NEWLINE_xXFemales must be surgically or biologically sterile or postmenopausal (amenorrheic for at least 12 months) or if of childbearing potential, must have a negative serum or urine pregnancy test within 72 hours before the start of the treatmentXx_NEWLINE_xXNegative serum pregnancy testXx_NEWLINE_xXFemale subject of childbearing potential must have a negative urine or serum pregnancy within 72 hours prior to receiving the first dose of study medication; if the urine test is positive or cannot be confirmed as negative, a serum pregnancy test will be requiredXx_NEWLINE_xXFemale participants of childbearing potential have a negative urine or serum pregnancy test and must be willing to use an adequate method of contraceptionXx_NEWLINE_xXFemale patients who are at least 10-years-old or are post-menarchal must have a negative serum or urine pregnancy test prior to enrollmentXx_NEWLINE_xXFemale patients of childbearing potential must have a negative urine or serum pregnancy test confirmed prior to enrollmentXx_NEWLINE_xXFor females of childbearing potential, a negative serum pregnancy test must be documented within 72 hours of receiving the first dose of vorinostatXx_NEWLINE_xXNegative pregnancy test (urine or serum) for female patients of childbearing potentialXx_NEWLINE_xXNegative serum pregnancy testXx_NEWLINE_xXFemale subject of childbearing potential should have a negative urine or serum pregnancy within 72 hours prior to receiving the first dose of study medication; if the urine test is positive or cannot be confirmed as negative, a serum pregnancy test will be requiredXx_NEWLINE_xXFemale subject of childbearing potential should have a negative urine or serum pregnancy within 72 hours prior to receiving the first dose of study medication; if the urine test is positive or cannot be confirmed as negative, a serum pregnancy test will be requiredXx_NEWLINE_xXFemale subject's of childbearing potential must have a negative serum pregnancy test within 72 hours prior to receiving the first dose of study medicationXx_NEWLINE_xXPregnant or breastfeeding; a negative serum pregnancy test is required no more than 7 days before study entryXx_NEWLINE_xXHas negative serum or urine pregnancy test for subjects of childbearing potentialXx_NEWLINE_xXFemale subjects of childbearing potential should have a negative urine or serum pregnancy within 72 hours prior to receiving the first dose of study medication; if the urine test is positive or cannot be confirmed as negative, a serum pregnancy test will be requiredXx_NEWLINE_xXFemales must be surgically or biologically sterile or postmenopausal (amenorrheic for at least 12 months) or if of childbearing potential, must have a negative serum or urine pregnancy test within 72 hours before the start of the treatmentXx_NEWLINE_xXNegative urine pregnancy test and/or serum pregnancy test within 7 days of initiation of therapyXx_NEWLINE_xXFemale subject of childbearing potential should have a negative urine or serum pregnancy within 72 hours prior to receiving the first dose of study medication; if the urine test is positive or cannot be confirmed as negative, a serum pregnancy test will be requiredXx_NEWLINE_xXFemale subject of childbearing potential should have a negative urine or serum pregnancy within 72 hours prior to receiving the first dose of study medication; if the urine test is positive or cannot be confirmed as negative, a serum pregnancy test will be requiredXx_NEWLINE_xXPregnant or breastfeeding; a negative serum pregnancy test is required no more than 7 days before study entryXx_NEWLINE_xXFemale subject of childbearing potential should have a negative urine or serum pregnancy within 72 hours prior to receiving the first dose of study medication; if the urine test is positive or cannot be confirmed as negative, a serum pregnancy test will be requiredXx_NEWLINE_xXNegative pregnancy testXx_NEWLINE_xXFemale subject of childbearing potential should have a negative urine or serum pregnancy within 72 hours prior to receiving the first dose of study medication; if the urine test is positive or cannot be confirmed as negative, a serum pregnancy test will be requiredXx_NEWLINE_xXFemale subject of childbearing potential should have a negative urine or serum pregnancy within 72 hours prior to receiving the first dose of study medication; if the urine test is positive or cannot be confirmed as negative, a serum pregnancy test will be requiredXx_NEWLINE_xXNegative serum or urine pregnancy testXx_NEWLINE_xXFemale patient of childbearing potential has a negative urine or serum pregnancy test within 7 days prior to receiving the first dose of study medication; if the urine test is positive or cannot be confirmed as negative, a serum pregnancy test will be required; the serum pregnancy test must be negative for the patient to be eligibleXx_NEWLINE_xXFemale patients with reproductive potential who do not have a negative blood or urine pregnancy test at screeningXx_NEWLINE_xXNegative serum or urine pregnancy test within 72 hours of commencement of treatment in premenopausal womenXx_NEWLINE_xXPregnant or nursing (lactating) women, female study participants of reproductive potential must have a negative serum or urine pregnancy test within 48 hours before infusionXx_NEWLINE_xXPregnant or lactating women; female study participants of reproductive potential must have a negative serum or urine pregnancy test performed within 48 hours before infusionXx_NEWLINE_xXNegative serum pregnancy test with 72 hours prior to start of study drugXx_NEWLINE_xXFor Phase I and II: Negative urine or serum pregnancy test.Xx_NEWLINE_xXDONOR: Not pregnant as confirmed by negative serum or urine pregnancy test within 14 days prior to enrollment (if female)Xx_NEWLINE_xXFemale patient of childbearing potential must have a negative serum or urine pregnancy test beta-human chorionic gonadotropin (hCG) within 72 hours prior to first doses of study medication. If the urine test is positive or cannot be confirmed as negative, a serum pregnancy test will be requiredXx_NEWLINE_xXFemale patients of childbearing potential must have a negative serum or urine pregnancy testXx_NEWLINE_xXNegative pregnancy test, if applicableXx_NEWLINE_xXNegative pregnancy test (serum or urine) in premenopausal womenXx_NEWLINE_xXNegative serum or urine pregnancy test within 72 hours prior to registration for women of childbearing potentialXx_NEWLINE_xXPatients must have a documented negative pregnancy test (urine or serum) for women who have menstruation in the past 12 months and without sterilization surgeryXx_NEWLINE_xXFemale subject of childbearing potential should have a negative urine or serum pregnancy within 72 hours prior to receiving the first dose of study medication; if the urine test is positive or cannot be confirmed as negative, a serum pregnancy test will be requiredXx_NEWLINE_xXNegative pregnancy test done =< 7 days prior to registration, for persons of childbearing potential only\r\n* NOTE: If the urine test is positive or cannot be confirmed as negative, a serum pregnancy test will be requiredXx_NEWLINE_xXFemale subjects of childbearing potential should have a negative urine or serum pregnancy test within 72 hours of receiving first dose of study treatment; if the urine test is positive or cannot be confirmed as negative, a serum pregnancy test will be requiredXx_NEWLINE_xXFemale subject of childbearing potential should have a negative urine or serum pregnancy within 7 days of enrollment; if the urine test is positive or cannot be confirmed as negative, a serum pregnancy test will be requiredXx_NEWLINE_xXA negative serum pregnancy test (if female and aged between 18-55 years old).Xx_NEWLINE_xXWOCBP must be using highly effective and medically accepted method of contraception to avoid pregnancy throughout the study and for at least 3 months after the study ; 12. WOCBP must have a negative serum or urine pregnancy test within 72 hours prior to the start of study drug.Xx_NEWLINE_xXFemale subject of childbearing potential should have a negative urine or serum pregnancy test < 72 hours prior to receiving the first dose of study medication; if the urine test is positive or cannot be confirmed as negative, a serum pregnancy test will be requiredXx_NEWLINE_xXPregnant or breast-feeding. Female patients of childbearing age must have negative serum or urine pregnancy test within 1 week of beginning therapy.Xx_NEWLINE_xXNegative pregnancy testXx_NEWLINE_xXIf the participant is a female of childbearing potential, must have had a negative serum or urine pregnancy test within 14 days of the first dose of study drug and must not be breast feedingXx_NEWLINE_xXHave a negative urine pregnancy test at baseline.Xx_NEWLINE_xXNegative serum or urine pregnancy test (females of childbearing potential only).Xx_NEWLINE_xXNegative blood or urine pregnancy test at screeningXx_NEWLINE_xXFor childbearing female patients, negative serum or urine pregnancy test at screeningXx_NEWLINE_xXWOCBP must have a negative pregnancy test within 24 hours prior to Study Day 0.Xx_NEWLINE_xXA negative serum or urine pregnancy test during Screening,Xx_NEWLINE_xXORAL CAVITY SQUAMOUS CELL CARCINOMA COHORT: Negative urine/serum pregnancy test (females only) at the time of screening and within 24 hours of study treatment, if applicableXx_NEWLINE_xXHPV-ASSOCIATED OROPHARYNX SQUAMOUS CELL CARCINOMA: Negative urine/serum pregnancy test (females only) at the time of screening and within 24 hours of study treatment, if applicableXx_NEWLINE_xXWomen of childbearing potential (WOCBP): negative urine or serum pregnancy test\r\n* If the urine test is positive or cannot be confirmed as negative, a serum pregnancy test will be requiredXx_NEWLINE_xXWOCBP who has a positive urine pregnancy test within 72 hours before the first dose of study treatmentXx_NEWLINE_xXFemale subject of childbearing potential should have a negative urine or serum pregnancy test within 72 hours prior to receiving the first dose of study medication; if the urine test is positive or cannot be confirmed as negative, a serum pregnancy test will be requiredXx_NEWLINE_xXWomen of child-bearing potential (intact uterus) MUST have a negative serum or urine human chorionic gonadotropin (HCG) test within 72 hours prior to receiving the first dose of study medication. Patients of childbearing potential are those who have not been surgically sterilized or have not been free from menses for > 1 year. If the urine test is positive or cannot be confirmed as negative, a serum pregnancy test will be required.Xx_NEWLINE_xXFemale subjects of childbearing potential should have a negative serum pregnancy test within 72 hours of starting first dose of study drug.Xx_NEWLINE_xXFemale patient of childbearing potential has a negative urine or serum pregnancy test; if the urine test is positive or cannot be confirmed as negative, a serum pregnancy test will be required; the serum pregnancy test must be negative for the patient to be eligibleXx_NEWLINE_xXFemale subject of childbearing potential should have a negative urine or serum pregnancy within 72 hours prior to receiving the first dose of study medication. If the urine test is positive or cannot be confirmed as negative, a serum pregnancy test will be requiredXx_NEWLINE_xXFemale subject of childbearing potential should have a negative urine or serum pregnancy within 72 hours prior to receiving the first dose of study medication; if the urine test is positive or cannot be confirmed as negative, a serum pregnancy test will be requiredXx_NEWLINE_xXWithin 14 days prior to day 1 of protocol therapy unless otherwise stated: Women of childbearing potential (WOCBP): negative urine or serum pregnancy test; if the urine test is positive or cannot be confirmed as negative, a serum pregnancy test will be requiredXx_NEWLINE_xXFemale subject of childbearing potential should have a negative urine or serum pregnancy within 72 hours prior to receiving the first dose of study medication; if the urine test is positive or cannot be confirmed as negative, a serum pregnancy test will be requiredXx_NEWLINE_xXFemale subject of childbearing potential should have a negative urine or serum pregnancy test within 72 hours prior to receiving the first dose of study medication; if the urine test is positive or cannot be confirmed as negative, a serum pregnancy test will be requiredXx_NEWLINE_xXA woman of childbearing potential must have a negative serum or urine pregnancy test at screening within 14 days and again within 72 hours prior to dosingXx_NEWLINE_xXFemale patients of childbearing potential have positive urine or serum pregnancy test no more than 7 days prior to starting study drug.Xx_NEWLINE_xXFemale participants of childbearing potential must have a negative serum pregnancy test at screening and negative (serum or urine) pregnancy test within 72 hours before the first study-drug dose; if the urine test is positive or cannot be confirmed as negative, a serum pregnancy test will be required; the serum pregnancy test must be negative for the participant to be eligibleXx_NEWLINE_xXFemale patients with an intact uterus (unless amenorrheic for the last 24 months) must have a negative serum pregnancy test within 72 hours prior to administration of any treatmentXx_NEWLINE_xXFemale patients of childbearing potential must have a negative serum or urine pregnancy testXx_NEWLINE_xXTo be performed within 28 days prior to day 1 of protocol therapy: Female of childbearing potential: negative urine or serum pregnancy test\r\n* If the urine test is positive or cannot be confirmed as negative, a serum pregnancy test will be requiredXx_NEWLINE_xXA negative serum pregnancy test, if female of reproductive potentialXx_NEWLINE_xXFemale subject of childbearing potential should have a negative urine or serum pregnancy within 72 hours prior to receiving the first dose of study medication; if the urine test is positive or cannot be confirmed as negative, a serum pregnancy test will be requiredXx_NEWLINE_xXPregnancy test (urine or serum beta-human chorionic gonadotropin [HCG]) done within 72 hours before randomization must be negative (for women of childbearing potential only); if urine pregnancy results are positive or cannot be confirmed as negative, a serum pregnancy test will be requiredXx_NEWLINE_xXFemale subject of childbearing potential should have a negative urine or serum pregnancy within 72 hours prior to receiving the first dose of study medication; if the urine test is positive or cannot be confirmed as negative, a serum pregnancy test will be requiredXx_NEWLINE_xXFemale subject of childbearing potential should have a negative urine or serum pregnancy within 72 hours prior to receiving the first dose of study medication; if the urine test is positive or cannot be confirmed as negative, a serum pregnancy test will be requiredXx_NEWLINE_xXFemale subject of childbearing potential should have a negative urine or serum pregnancy within 72 hours prior to receiving the first dose of study medication; if the urine test is positive or cannot be confirmed as negative, a serum pregnancy test will be requiredXx_NEWLINE_xXFemale patients of childbearing potential should have a negative urine or serum pregnancy test within 24 hours prior to receiving the first dose of study medication; if the urine test is positive or cannot be confirmed as negative, a serum pregnancy test will be requiredXx_NEWLINE_xXNegative pregnancy testXx_NEWLINE_xXFemale patients with reproductive potential who do not have a negative blood or urine pregnancy test at Screening or who are lactating.Xx_NEWLINE_xXFemale subject of childbearing potential should have a negative urine or serum pregnancy within 72 hours prior to receiving the first dose of study medication; if the urine test is positive or cannot be confirmed as negative, a serum pregnancy test will be requiredXx_NEWLINE_xXWomen of childbearing potential should have a negative urine or serum pregnancy within 72 hours prior to receiving the first dose of study medication; if the urine test is positive or cannot be confirmed as negative, a serum pregnancy test will be requiredXx_NEWLINE_xXA WOCBP who has a positive urine pregnancy test within 72 hours prior to study treatment start; if the urine test is positive or cannot be confirmed as negative, a serum pregnancy test will be requiredXx_NEWLINE_xXWoman of childbearing potential (WOCBP): negative urine or serum pregnancy test; if the urine test is positive or cannot be confirmed as negative, a serum pregnancy test will be requiredXx_NEWLINE_xXNegative pregnancy test done =< 7 days prior to registration, for persons of childbearing potential only\r\n* NOTE: If the urine test is positive or cannot be confirmed as negative, a serum pregnancy test will be required\r\n* NOTE: Merck requires an additional pregnancy test if eligibility pregnancy test is > 72 hours prior to first doseXx_NEWLINE_xXFemale subject of childbearing potential should have two negative urine or serum pregnancy test, one at 10-14 days before first dose of study drug and another within 24 hours prior to receiving the first dose of study medication; if the urine test is positive or cannot be confirmed as negative, a serum pregnancy test will be requiredXx_NEWLINE_xXFemale subject of childbearing potential should have a negative urine or serum pregnancy per institutional guidelines for high-dose melphalan and autologous transplant; if the urine test is positive or cannot be confirmed as negative, a serum pregnancy test will be requiredXx_NEWLINE_xXFemales only:\r\n* Urine or serum pregnancy test negative assessed within seven (7) days prior to the start of therapyXx_NEWLINE_xXAnd have a negative urine pregnancy test at ScreeningXx_NEWLINE_xXPatients of childbearing potential must have negative pregnancy serum test within 72 hours of being dosedXx_NEWLINE_xXFemale patient, if of childbearing potential, has a negative serum pregnancy test within 72 hours of taking study medication and agrees to abstain from activities that could result in pregnancy from enrollment through 120 days after the last dose of study treatmentXx_NEWLINE_xXWomen of childbearing potential must plan to have a urine or serum pregnancy test within 72 hours prior to receiving the first dose of study medication; if the urine test is positive or cannot be confirmed as negative, a negative serum pregnancy test will be requiredXx_NEWLINE_xXPatients of childbearing potential must have negative pregnancy serum test within 72 hours of being dosedXx_NEWLINE_xXPregnant or nursing (lactating) women. NOTE: female study participants of reproductive potential must have a negative serum or urine pregnancy test performed within 48 hours before infusionXx_NEWLINE_xXA negative pregnancy test (if female).Xx_NEWLINE_xXHave a negative urine or serum pregnancy test at screeningXx_NEWLINE_xXHave 2 negative pregnancy tests as verified by the Investigator prior to starting any IP therapy: serum pregnancy test at screening and negative serum or urine pregnancy test (Investigator's discretion) within 72 hours prior to starting treatment with IP (Cycle 1, Day 1). They must agree to ongoing pregnancy testing during the course of the study (before beginning each subsequent cycle of treatment), and after the last dose of any IP. This applies even if the subject practices complete abstinence[2] from heterosexual contact.Xx_NEWLINE_xXWomen of childbearing potential (i.e., menstruating women) must have a negative urine pregnancy test (positive urine tests are to be confirmed by serum test)Xx_NEWLINE_xXFemale subjects of childbearing potential must have a negative urine or serum pregnancy within 72 hours prior to receiving the first dose of study drug; if the urine test is positive or cannot be confirmed as negative, a serum pregnancy test will be required and subject also should agree to use an adequate method of contraception starting with screening through 30 days after the last dose of study therapy (if sexually active).Xx_NEWLINE_xXFemale subjects must be of non-childbearing potential or, if of childbearing potential, must have a negative urine or serum pregnancy test within 72 hours prior to taking study medication. If the urine test is positive or cannot be confirmed as negative, a serum pregnancy test will be required. The serum pregnancy test must be negative for the subject to be eligible. Non-childbearing potential is defined as (by other than medical reasons):Xx_NEWLINE_xXNegative serum or urine pregnancy test (investigator's discretion; sensitivity of at least 25 mIU/mL) within 72 hours prior to starting IP in the extension phase. (Note: subjects must have negative serum or urine pregnancy test prior to dosing on Day 1 of each treatment cycle in the extension phase.)Xx_NEWLINE_xXFemale patients with reproductive potential who do not have a negative blood or urine pregnancy test at Screening.Xx_NEWLINE_xXNegative serum pregnancy testXx_NEWLINE_xXNegative urine/serum pregnancy test, if applicableXx_NEWLINE_xXFemale subjects of childbearing potential should have a negative urine or serum pregnancy within 72 hours prior to receiving the first dose of study medication; if the urine test is positive or cannot be confirmed as negative, a serum pregnancy test will be requiredXx_NEWLINE_xXFemale subject of childbearing potential should have a negative urine or serum pregnancy test within 72 hours prior to receiving retreatment with study medicationXx_NEWLINE_xXNegative serum or urine pregnancy test within 3 days prior to start of study treatment.Xx_NEWLINE_xXFemales must be surgically or biologically sterile or postmenopausal (amenorrheic for at least 12 months) or if of childbearing potential, must have a negative serum or urine pregnancy test within 72 hours before the start of the treatmentXx_NEWLINE_xXNegative urine pregnancy testXx_NEWLINE_xXFemale subject of childbearing potential should have a negative urine or serum pregnancy within 72 hours prior to receiving the first dose of study medication; if the urine test is positive or cannot be confirmed as negative, a serum pregnancy test will be requiredXx_NEWLINE_xXPregnant or lactating women; female study participants of reproductive potential must have a negative serum pregnancy test at enrollment; a urine or serum pregnancy test will be performed within 48 hours before the RNA CART19 infusionXx_NEWLINE_xXFemale subject of childbearing potential should have a negative urine or serum pregnancy within 72 hours prior to receiving the first dose of study medication; if the urine test is positive or cannot be confirmed as negative, a serum pregnancy test will be requiredXx_NEWLINE_xXPregnant or breastfeeding women; female study participants of reproductive potential must have a negative urine pregnancy test of enrollment; a serum pregnancy test will be performed within 2 weeks before infusionXx_NEWLINE_xXA negative serum pregnancy test (if female and aged between 18-55 years old).Xx_NEWLINE_xXPregnant and/or breastfeeding; patient must have a negative urine pregnancy test within 14 days of study entryXx_NEWLINE_xXDocumentation of negative pregnancy test.Xx_NEWLINE_xXFemale of childbearing potential only: negative urine or serum pregnancy test; if the urine test is positive or cannot be confirmed as negative, a serum pregnancy test will be required (within 14 days prior to day 1 of protocol therapy)Xx_NEWLINE_xXFemale subjects of childbearing potential should have a negative urine or serum pregnancy within 72 hours prior to receiving the first dose of study medication; if the urine test is positive or cannot be confirmed as negative, a serum pregnancy test will be requiredXx_NEWLINE_xXAnd have a negative urine or serum pregnancy test at screeningXx_NEWLINE_xXFemale subject of childbearing potential should have a negative urine or serum pregnancy within 72 hours prior to receiving the first dose of study medication; if the urine test is positive or cannot be confirmed as negative, a serum pregnancy test will be requiredXx_NEWLINE_xXFemale subjects of childbearing potential must have a negative serum pregnancy test within 7 days prior to study entry (positive urine tests are to be confirmed by serum test)Xx_NEWLINE_xXFemale participants of childbearing potential must have a negative serum pregnancy within 72 hours prior to receiving the first dose of study medication; if the urine test is positive or cannot be confirmed as negative, a serum pregnancy test will be requiredXx_NEWLINE_xXFemale subject of childbearing potential should have a negative urine or serum pregnancy within 72 hours prior to receiving the first dose of study medication; if the urine test is positive or cannot be confirmed as negative, a serum pregnancy test will be requiredXx_NEWLINE_xXFemale subject of childbearing potential should have a negative urine or serum pregnancy within 72 hours prior to receiving the first dose of study medication; if the urine test is positive or cannot be confirmed as negative, a serum pregnancy test will be requiredXx_NEWLINE_xXFemale subject of childbearing potential should have a negative urine or serum pregnancy within 7 days prior to receiving the first dose of study medication; if the urine test is positive or cannot be confirmed as negative, a serum pregnancy test will be requiredXx_NEWLINE_xXFor female subjects with reproductive potential: a negative serum pregnancy testXx_NEWLINE_xXFemale patient of childbearing potential has a negative serum or urine pregnancy test within 14 days prior to administration of study therapyXx_NEWLINE_xXFemale subject of childbearing potential should have a negative urine or serum pregnancy test within 72 hours prior to receiving the first dose of study medication; if the urine test is positive or cannot be confirmed as negative, a serum pregnancy test will be requiredXx_NEWLINE_xXNegative urine or serum pregnancy test done =< 7 days prior to registration for females who are post-menarchalXx_NEWLINE_xXFemale subjects of childbearing potential should have a negative urine or serum pregnancy within 72 hours prior to receiving the first dose of study medication; if the urine test is positive or cannot be confirmed as negative, a serum pregnancy test will be requiredXx_NEWLINE_xXPregnant and/or breastfeeding; patient must have a negative urine pregnancy test within 5 days of study entryXx_NEWLINE_xXFemale subjects of childbearing potential should have a negative urine or serum pregnancy within 72 hours prior to receiving the first dose of study medication; if the urine test is positive or cannot be confirmed as negative, a serum pregnancy test will be requiredXx_NEWLINE_xXFemale subject of childbearing potential should have a negative urine or serum pregnancy within 72 hours prior to receiving the first dose of study medication; if the urine test is positive or cannot be confirmed as negative, a serum pregnancy test will be requiredXx_NEWLINE_xXWomen of childbearing potential (WOCP) must not be pregnant or breast-feeding. A negative serum or urine pregnancy test is required within 72 hours of study registration. If the urine test cannot be confirmed as negative, a serum pregnancy test will be required.Xx_NEWLINE_xXFemale subjects of childbearing potential should have a negative urine or serum pregnancy test; if the urine test is positive or cannot be confirmed as negative, a serum pregnancy test will be requiredXx_NEWLINE_xXFemale subject of childbearing potential should have a negative serum pregnancy within 72 hours prior to receiving the first dose of study medication; if the urine test is positive or cannot be confirmed as negative, a serum pregnancy test will be requiredXx_NEWLINE_xXMust have a negative serum pregnancy testXx_NEWLINE_xXFemale subject of childbearing potential should have a negative urine or serum pregnancy within 72 hours prior to receiving the first dose of study medication; if the urine test is positive or cannot be confirmed as negative, a serum pregnancy test will be requiredXx_NEWLINE_xXEvidence of post-menopausal status or negative urinary or serum pregnancy test.Xx_NEWLINE_xXNegative pregnancy test at screeningXx_NEWLINE_xXNegative serum pregnancy test for female subjects (unless surgically sterile or greater than two years post-menopausal)Xx_NEWLINE_xXFemales of childbearing potential must have a negative serum or urine pregnancy test at screeningXx_NEWLINE_xXNegative serum pregnancy test; if, on cycle 1 day 1, greater than 72 hours has elapsed since the last negative result, a serum pregnancy test must be repeated and be negative on cycle 1 day 1 (C1D1) for the patient to remain eligibleXx_NEWLINE_xXNegative urine or serum pregnancy test for females of childbearing potentialXx_NEWLINE_xXFemale subjects of childbearing potential must not be pregnant or breast-feeding; female subjects of childbearing potential must have a negative serum or urine pregnancy test; (pregnancy test must be repeated within 72 hours prior to the start of therapy)Xx_NEWLINE_xXmust have a negative urine pregnancy test at Screening, andXx_NEWLINE_xXFemale patient of childbearing potential has a negative urine or serum pregnancy test; if the urine test is positive or cannot be confirmed as negative, a serum pregnancy test will be required; the serum pregnancy test must be negative for the patient to be eligibleXx_NEWLINE_xXNegative serum pregnancy test at screening.Xx_NEWLINE_xXFemale subject of childbearing potential should have a negative urine or serum pregnancy within 2 weeks prior to receiving the first dose of study medication; if the urine test is positive or cannot be confirmed as negative, a serum pregnancy test will be requiredXx_NEWLINE_xXIf a female of childbearing potential, had a negative serum pregnancy test within 14 days before enrollment, or within 72 hours before enrollment where requiredXx_NEWLINE_xXFemale participant who is post-menarchal must have a negative urine or serum pregnancy testXx_NEWLINE_xXFemales of child-bearing potential (not surgically sterilized and between menarche and 1 year post menopause) must test negative for pregnancy within 48 hours prior to any initial study procedure based on a serum pregnancy test; both sexually active males and females of reproductive potential must agree to use a reliable method of birth control, as determined by the patient and their health care team, during the study and for 3 months following the last dose of study drug; if subject uses appropriate contraceptive methods (the use of two forms at the same time) from the time of the initial serum pregnancy test, then the subsequent pregnancy test can be done within 72 hours of receiving study drug administration; if appropriate contraceptive measures are not begun immediately with the first serum pregnancy test, then subsequent serum pregnancy tests must be done within 48 hours prior to the study drug administrationXx_NEWLINE_xXPregnant or lactating women; the safety of this therapy on unborn children is not known; female study participants of reproductive potential must have a negative serum or urine pregnancy test performed within 48 hours before infusionXx_NEWLINE_xXNegative pregnancy test for WOCBPXx_NEWLINE_xXPatients who are pregnant; pregnancy will be confirmed by negative urine testXx_NEWLINE_xXKnown pregnancy (negative serum or urine pregnancy test to be conducted within 7 days prior to enrollment) (Female only)Xx_NEWLINE_xXDONOR: Known pregnancy (negative serum or urine pregnancy test to be conducted within 7 days prior to enrollment) (Female only)Xx_NEWLINE_xXFemale patients must have a negative urine or serum pregnancy test at screening (pregnancy test not required for patients with bilateral oophorectomy and/or hysterectomy or for those patients who are > 1 year postmenopausal)Xx_NEWLINE_xXNegative pregnancy test (if female in reproductive years)Xx_NEWLINE_xXFemale patients of childbearing potential must have negative serum or urine pregnancy test; patient must not be pregnant or breast feedingXx_NEWLINE_xXFemale subject of childbearing potential should have a negative urine or serum pregnancy within 72 hours prior to receiving the first dose of study medication; if the urine test is positive or cannot be confirmed as negative, a serum pregnancy test will be requiredXx_NEWLINE_xXFemale patients who are pregnant or lactating – or planning to become pregnant within 6 months after the end of the treatment (female patients of child-bearing potential must have negative pregnancy test =< 72 hours before enrollment and randomization and must have a negative pregnancy test =< 72 hours prior to treatment start)Xx_NEWLINE_xXFemale subjects of childbearing potential as defined in Section 5.7.2 must have a negative urine or serum pregnancy within 72 hours prior to receiving the first dose of study medication. If the urine test is positive or cannot be confirmed as negative, a serum pregnancy test will be required.Xx_NEWLINE_xXFemale subject of childbearing potential should have a negative urine or serum pregnancy within 72 hours prior to receiving the first dose of study medication; if the urine test is positive or cannot be confirmed as negative, a serum pregnancy test will be requiredXx_NEWLINE_xXNegative pregnancy test.Xx_NEWLINE_xXNegative pregnancy test (if female in reproductive years)Xx_NEWLINE_xXPregnant or breast-feeding patients. Female patients of childbearing age must have negative serum or urine pregnancy test within 1 week of beginning therapyXx_NEWLINE_xXNegative pregnancy test if applicableXx_NEWLINE_xXFemale subject of childbearing potential should have a negative urine or serum pregnancy within 72 hours prior to receiving the first dose of study medication; if the urine test is positive or cannot be confirmed as negative, a serum pregnancy test will be requiredXx_NEWLINE_xXFemale subject of childbearing potential must have a negative urine or serum pregnancy within 72 hours prior to receiving the first dose of study medication; if the urine test is positive or cannot be confirmed as negative, a serum pregnancy test will be requiredXx_NEWLINE_xXFemale patients of childbearing potential must have a negative serum or urine pregnancy test, whichever is considered standard by the institutionXx_NEWLINE_xXFemale patients of childbearing potential must have a negative urine or serum pregnancy test confirmed prior to enrollment.Xx_NEWLINE_xXFemale patients of childbearing potential must have a negative urine or serum pregnancy test confirmed within 2 weeks prior to enrollment.Xx_NEWLINE_xXFor women of childbearing potential, a negative serum or urine pregnancy test with sensitivity less than 50 mIU/m within 72 hours before the start of study medicationXx_NEWLINE_xXAnd have a negative serum pregnancy test at screeningXx_NEWLINE_xXFemales must be surgically or biologically sterile or postmenopausal (amenorrheic for at least 12 months) or if of childbearing potential, must have a negative serum or urine pregnancy test within 72 hours before the start of the treatmentXx_NEWLINE_xXNegative urine or serum pregnancy test within 7 days before Day 1 (first dose of study medication) if female subject is of childbearing potential (WOCBP).Xx_NEWLINE_xXNegative serum pregnancy test for femalesXx_NEWLINE_xXFemale subjects of childbearing potential must have a negative serum pregnancy test at screening within 96 hours prior to the first study dose.Xx_NEWLINE_xXFemale patients of childbearing potential must have a negative serum or urine pregnancy test at the time of enrollmentXx_NEWLINE_xXNegative serum pregnancy test.Xx_NEWLINE_xXUrine pregnancy test for women of childbearing potential (defined as not post-menopausal for 12 consecutive months or no previous surgical sterilizations); a negative urine pregnancy test is required within 48 hours of initiating study drugXx_NEWLINE_xXRECURRENT/ PROGRESSIVE DIPG (STRATUM 1): Female patients of childbearing potential must have a negative serum or urine pregnancy testXx_NEWLINE_xXNON-PROGRESSED DIPG (STRATUM 2): Female patients of childbearing potential must have a negative serum or urine pregnancy testXx_NEWLINE_xXFemale subject of childbearing potential should have a negative urine or serum pregnancy within 72 hours prior to receiving the first dose of study medication; if the urine test is positive or cannot be confirmed as negative, a serum pregnancy test will be requiredXx_NEWLINE_xXFemale patient of childbearing potential should have a negative urine or serum pregnancy test within 72 hours.Xx_NEWLINE_xXPost-menarchal female has had negative serum pregnancy test within 7 days prior to enrollmentXx_NEWLINE_xXINCLUSION CRITERIA - HPC-A CELL DONOR: Not pregnant as confirmed by negative serum or urine pregnancy test within 7 days prior to enrollment (if female)Xx_NEWLINE_xX(Female only) negative serum or urine pregnancy test (to be conducted within 7 days prior to enrollment)Xx_NEWLINE_xX(Female only) is not pregnant (negative serum or urine pregnancy test to be conducted within 7 days prior to admission for transplant)Xx_NEWLINE_xXDONOR: (Female only) is not pregnant (negative serum or urine pregnancy test to be conducted within 7 days prior to enrollment)Xx_NEWLINE_xXPregnant or lactating (female participant of childbearing potential must have negative serum or urine pregnancy test required within 7 days prior to start of treatment)Xx_NEWLINE_xXFemale patients of childbearing potential must have a negative urine or serum pregnancy test confirmed prior to enrollment.Xx_NEWLINE_xXA negative serum pregnancy test (if female and aged between 18-55 years old).Xx_NEWLINE_xXWOCBP must have a negative serum pregnancy test within 7 days prior to receiving investigational product and a negative urine pregnancy test on Day 1 of each Cycle;Xx_NEWLINE_xXPregnant or lactating (female participant of childbearing potential must have negative serum or urine pregnancy test required within 7 days prior to start of treatment)Xx_NEWLINE_xXDONOR: Not pregnant as confirmed by negative serum or urine pregnancy test within 14 days prior to enrollment (if female)Xx_NEWLINE_xXIf the participant is a female of childbearing potential, must have had a negative serum or urine pregnancy test within 14 days of the first dose of study drug and must not be breast feeding.Xx_NEWLINE_xXNot pregnant as confirmed by negative serum or urine pregnancy test within 14 days prior to enrollment (if female)Xx_NEWLINE_xXFor women of childbearing potential, a negative serum or urine pregnancy test with sensitivity less than 50 mIU/m within 72 hours before the start of study medicationXx_NEWLINE_xXIf female and of childbearing potential, documentation of negative pregnancy test (serum or urine) within 7 days prior to first doseXx_NEWLINE_xXNegative serum or urine pregnancy test within 7 days prior to and including the morning of day -7 (first potential day of research blood draw and tumor biopsy)Xx_NEWLINE_xXA negative serum pregnancy test (if female)Xx_NEWLINE_xXFemale patients of childbearing potential must have a negative serum or urine pregnancy test result at time of pre-treatment screening.Xx_NEWLINE_xXFemales of childbearing potential must have a negative serum or urine pregnancy test within 72 hours prior to start of ipilimumabXx_NEWLINE_xXPatient must not be pregnant and/or breastfeeding; patient must have a negative urine pregnancy test within seven days of study entryXx_NEWLINE_xXNegative serum or urine pregnancy test at the time of first dose for WOCBP.Xx_NEWLINE_xXDONOR: Not pregnant as confirmed by negative serum or urine pregnancy test within 14 days prior to enrollment (if female)Xx_NEWLINE_xXNegative pregnancy testXx_NEWLINE_xXFemales with reproductive potential: Must have a negative serum or urine pregnancy test within 7 days prior to the first dose of any study drug.Xx_NEWLINE_xXNegative pregnancy testXx_NEWLINE_xXNegative pregnancy testXx_NEWLINE_xXNegative pregnancy testXx_NEWLINE_xXNegative pregnancy testXx_NEWLINE_xXnegative serum pregnancy testXx_NEWLINE_xXNegative urine pregnancy test (negative serum confirmatory pregnancy test if urine test is positive)Xx_NEWLINE_xXPregnant or breast feeding patients. Female patients of childbearing age must have negative serum or urine pregnancy test within 1 week of beginning therapy.Xx_NEWLINE_xXNegative pregnancy testXx_NEWLINE_xXPregnant and/or breastfeeding; patient must have a negative serum or urine pregnancy test within 72 hours of study entryXx_NEWLINE_xXFemale subject of childbearing potential should have a negative urine or serum pregnancy within 72 hours prior to receiving the first dose of study medication; if the urine test is positive or cannot be confirmed as negative, a serum pregnancy test will be requiredXx_NEWLINE_xXFemales must be surgically or biologically sterile or postmenopausal (amenorrheic for at least 12 months) or if of childbearing potential, must have a negative urine pregnancy test within 72 hours or serum pregnancy test within 2 weeks of signing the informed consent documentXx_NEWLINE_xXMust have a negative serum pregnancy test at screening and day -1, andXx_NEWLINE_xXPregnant or nursing women; a negative pregnancy test (serum or urine) =< 3 days prior to starting study treatmentXx_NEWLINE_xXFemale subjects of childbearing potential must have either a negative urine or a negative serum pregnancy test within seven (7) days of first dose of pembrolizumab; if a urine test is positive or cannot be confirmed as negative, a serum pregnancy test will be requiredXx_NEWLINE_xXFemale subjects of childbearing potential, must have either a negative urine or a negative serum pregnancy test within seven (7) days of first dose of pembrolizumab; if a urine test is positive or cannot be confirmed as negative, a serum pregnancy test will be requiredXx_NEWLINE_xXFemale participants of childbearing potential must have a negative urine or serum pregnancy test within 72 hours prior to receiving the first dose of study therapyXx_NEWLINE_xXFemale subject of childbearing potential should have a negative urine or serum pregnancy test within 72 hours prior to receiving the first dose of study medication; if the urine test is positive or cannot be confirmed as negative, a serum pregnancy test will be requiredXx_NEWLINE_xXFOCBP must have a negative urine or serum pregnancy test within 14 days prior to registration on study.Xx_NEWLINE_xXPregnancy or nursing: All females of childbearing age must have a negative serum or urine pregnancy test < 7 days before study drug administrationXx_NEWLINE_xXFemale patients who are pregnant (female patients of child-bearing potential must have a negative serum pregnancy test =< 14 days prior to surgery or 15 to 30 days prior to surgery with a negative urine pregnancy test the morning of surgery)Xx_NEWLINE_xXPre-menopausal women without a negative serum or urine pregnancy test within 4 weeks of starting treatmentXx_NEWLINE_xXWomen of child-bearing potential (intact uterus) should have a negative urine or serum pregnancy within 72 hours prior to receiving the first dose of study medication; subjects of childbearing potential are those who have not been surgically sterilized or have not been free from menses for > 1 year; if the urine test is positive or cannot be confirmed as negative, a serum pregnancy test will be requiredXx_NEWLINE_xXPatients who are pregnant; the absence of pregnancy will be confirmed by negative urine testXx_NEWLINE_xXNegative pregnancy testXx_NEWLINE_xXUrine or serum pregnancy test: negative for female patients of childbearing potentialXx_NEWLINE_xXNegative pregnancy testXx_NEWLINE_xX(Female only) Known pregnancy (negative serum or urine pregnancy test to be conducted within 14 days prior to enrollment)Xx_NEWLINE_xXPost-menopausal or negative urine and/or blood pregnancy testXx_NEWLINE_xXThey are not pregnant (i.e., female patients must have a negative serum pregnancy test at screening);Xx_NEWLINE_xXAll WOCBP MUST have a negative pregnancy test prior to first receiving study medicationXx_NEWLINE_xXPregnant and/or breastfeeding; female patients must have a negative urine pregnancy test within 14 days of study entryXx_NEWLINE_xXNegative pregnancy test (urine and blood tests)Xx_NEWLINE_xXHave two negative pregnancy tests as verified by the investigator prior to starting any IP therapy: serum pregnancy test at screening and negative serum or urine pregnancy test (investigator's discretion) within 72 hours prior to starting treatment with IP (Cycle 1, Day 1). They must agree to ongoing pregnancy testing during the course of the study (before beginning each subsequent cycle of treatment), and after the last dose of any IP. This applies even if the subject practices complete abstinence2 from heterosexual contact.Xx_NEWLINE_xXThe patient is pregnant as confirmed by urine or serum pregnancy testing,Xx_NEWLINE_xXA negative serum pregnancy test at Screening followed by a negative urine pregnancy test on the day of surgery or day of admission for female patients of childbearing potentialXx_NEWLINE_xXFemale subject of childbearing potential should have a negative urine or serum pregnancy within 72 hours prior to receiving the first dose of study medication; if the urine test is positive or cannot be confirmed as negative, a serum pregnancy test will be requiredXx_NEWLINE_xXFemale subjects of childbearing potential should have a negative urine or serum pregnancy within 14 days prior to C11-AMT PET scan; if the urine test is positive or cannot be confirmed as negative, a serum pregnancy test will be requiredXx_NEWLINE_xXALL PARTICIPANTS: A negative serum or urine pregnancy test for woman of childbearing potentialXx_NEWLINE_xXNegative serum pregnancy testXx_NEWLINE_xXIf a female and pre-menopausal, must have a negative pregnancy test.Xx_NEWLINE_xXWoman of childbearing potential, a negative serum or urine pregnancy testXx_NEWLINE_xXWoman of childbearing potential, a negative serum or urine pregnancy testXx_NEWLINE_xXFemale subject of childbearing potential should have a negative urine or serum pregnancy within 72 hours prior to registration; if the urine test is positive or cannot be confirmed as negative, a serum pregnancy test will be requiredXx_NEWLINE_xXIf of childbearing potential, negative pre-treatment urine or serum pregnancy testXx_NEWLINE_xXFemale patients of childbearing potential must have a negative serum or urine pregnancy test within 7 days of enrollmentXx_NEWLINE_xXFemale subject of childbearing potential must have a negative urine or serum pregnancy within 72 hours prior to receiving the first dose of study medication; if the urine test is positive or cannot be confirmed as negative, a serum pregnancy test will be requiredXx_NEWLINE_xXAnd have a negative urine or serum pregnancy test at screeningXx_NEWLINE_xXFemale subjects of childbearing potential (unless they have a negative serum or urine pregnancy test within 3 days prior to start of study treatment)Xx_NEWLINE_xXFemale patients must have a negative urine pregnancy testXx_NEWLINE_xXFor females: negative urine pregnancy test or post-menopausal for at least 2 years or patient has had a hysterectomyXx_NEWLINE_xXNegative urine pregnancy test within 36 hours prior to study drug administration, if of childbearing potentialXx_NEWLINE_xXFemale subject of childbearing potential must have a negative pregnancy test within 72 hours prior to enrollment.Xx_NEWLINE_xXA negative serum pregnancy test at Screening followed by a negative urine pregnancy test on the day of surgery or day of admission for female patients of childbearing potentialXx_NEWLINE_xXFemale subject of childbearing potential must have a negative urine or serum pregnancy within 72 hours prior to receiving the first dose of study medication; if the urine test is positive or cannot be confirmed as negative, a serum pregnancy test will be requiredXx_NEWLINE_xXFemale subjects with reproductive potential must have negative serum or urine pregnancy testXx_NEWLINE_xXFemale subject of childbearing potential should have a negative urine or serum pregnancy test within 72 hours prior to dosing.Xx_NEWLINE_xXFemale subject of childbearing potential should have a negative urine or serum pregnancy within 72 hours prior to receiving the first dose of study medication; if the urine test is positive or cannot be confirmed as negative, a serum pregnancy test will be requiredXx_NEWLINE_xXFemale subject of childbearing potential should have a negative urine or serum pregnancy within 72 hours prior to receiving the first dose of study medication; if the urine test is positive or cannot be confirmed as negative, a serum pregnancy test will be requiredXx_NEWLINE_xXFemale subject of childbearing potential should have a negative urine or serum pregnancy within 72 hours prior to receiving the first dose of study medication; if the urine test is positive or cannot be confirmed as negative, a serum pregnancy test will be requiredXx_NEWLINE_xXFemale patients of childbearing potential should have a negative urine or serum pregnancy within 72 hours prior to receiving the first dose of study medication; if the urine test is positive or cannot be confirmed as negative, a serum pregnancy test will be requiredXx_NEWLINE_xX